SYRE

Business Context and Reporting Period

Spyre Therapeutics, Inc. (formerly Aeglea BioTherapeutics, Inc.) is a clinical-stage biotechnology company focused on developing next-generation therapeutics for inflammatory bowel disease (IBD). This Form 10-Q covers the quarterly period ended September 30, 2024. The company operates in a single segment and is headquartered in Waltham, Massachusetts. Following a strategic asset acquisition in June 2023, the company's pipeline now centers on monoclonal antibody programs (SPY001, SPY002, SPY003) licensed from Paragon Therapeutics, Inc.

Key Financial Metrics

Note: All figures in millions unless otherwise noted. The company has no commercial product revenue.

Material Changes vs. Prior Period

• Revenue: The company recognized $0 revenue for the three and nine months ended September 30, 2024, compared to $0.9 million in development fee revenue for the same period in 2023 (attributable to the legacy Immedica agreement).
• Net Loss: Net loss increased to $69.0 million for Q3 2024 from $40.1 million in Q3 2023. For the nine-month period, net loss was $151.7 million compared to $275.6 million in 2023. The year-over-year improvement in the nine-month loss is primarily due to the absence of a $130.2 million non-cash charge for acquired in-process research and development (IPR&D) and an $83.5 million non-cash expense related to the change in fair value of a forward contract liability recorded in 2023.
• Operating Expenses: R&D expenses increased 81% year-over-year for Q3 2024 ($44.7M vs $24.7M) driven by increased preclinical/clinical activities and manufacturing costs for the IBD pipeline. G&A expenses increased 24% ($10.6M vs $8.6M) primarily due to higher stock-based compensation.
• Other Income/Expense: Interest income increased significantly to $5.2 million in Q3 2024 from $1.3 million in Q3 2023 due to higher investment balances. Conversely, the company recorded a $18.8 million expense in "Other (expense) income, net" for Q3 2024, driven by a change in the fair value of the Contingent Value Right (CVR) liability.

Guidance, Outlook, and Risks

• Liquidity Outlook: Management states that as of September 30, 2024, the company has sufficient resources (cash, cash equivalents, and marketable securities of $414.2 million) to fund operations for at least one year from the issuance date of the report. Additional financing will be required to fund future R&D and commercialization.
• Capital Raises: In March 2024, the company completed a private placement of Series B Preferred Stock raising approximately $180 million. In September 2024, the company filed an S-3 shelf registration and entered an At-The-Market (ATM) sales agreement, selling shares for net proceeds of $11.8 million.
• Development Milestones:
  • SPY001 (anti-α4β7): First-in-human (FIH) Phase 1 trial initiated in June 2024; interim safety and PK data expected by year-end 2024.
  • SPY002 (anti-TL1A): Two FIH trials expected to initiate in Q4 2024.
  • SPY003 (anti-IL-23): FIH trial expected to initiate in Q1 2025.
• Risks and Contingencies:
  • Going Concern: The company has never been profitable and expects to incur significant losses for the foreseeable future. Failure to raise additional capital could force delays or discontinuation of programs.
  • Third-Party Reliance: The company relies heavily on Paragon Therapeutics for discovery and development services under the Paragon Agreement. Related party expenses totaled $21.2 million for the nine months ended Sept 30, 2024.
  • CVR Liability: The company holds a CVR liability of $60.9 million (as of Sept 30, 2024) related to the monetization of legacy assets, which fluctuates based on fair value estimates.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $414.2 million liquidity position against the accelerating burn rate driven by Phase 1 clinical trials.
• Related Party Transactions: Review the terms of the Paragon Agreement and the $14.5 million payable to Paragon as of September 30, 2024, to understand ongoing cash obligations.
• Stock-Based Compensation: Assess the impact of the $35.6 million stock-based compensation expense (nine months 2024) on future dilution, particularly regarding the Parapyre Option Obligation.
• CVR Liability Volatility: Monitor the $60.9 million CVR liability, as changes in fair value estimates significantly impact reported net loss without affecting cash flow.
• ATM Program: Track the utilization of the $200 million ATM facility and its potential dilutive effect on existing shareholders.